Cat. No.: HY-L171

Anti-Hematopathy Compound Library

83 Cited Publications

Customer Review

Based on 83 publication(s) in Google Scholar

Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs.

MCE designs a unique collection of 4,303 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

For pre-dissolved solutions, 10 mM for compounds with the solubility not lower than 10 mM, 2 mM for compounds with solubility between 2 mM and 10 mM, and 3 mg/mL for compounds with unconfirmed molecular weight and solubility not lower than 3 mg/mL.

PDF
Excel
SDF
Manual

Size

Price

Stock

Quantity

In-stock

(2-3 weeks)

Get a Quotation Now

In-stock

(2-3 weeks)

Get a Quotation Now

(2-3 weeks)

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Description & Advantages
Product Details
- Formulation
- Layout
- Container
- Storage
- Shipping
Publications (83)
Documentation
Composition

Description & Advantages

• A unique collection of 4,303 anti-hematopathy compounds for high throughput screening (HTS) and high content screening (HCS).

• A useful tool for the discovery of anti-hematopathy diseases compounds such as aplastic anemia, mediterranean anemia, leukemia, haemophilia, etc.

• Bioactivity and safety confirmed by preclinical research and clinical trials. Some compounds have been approved by FDA.

• Structurally diverse, bioactive, and cell permeable.

• More detailed compound information with structure, IC50, and other chemical & biological data.

• High purity and quality validated by NMR and LC/MS.

• All compounds are in stock and continuously updated.

Product Details

Formulation

A collection of 4,303 bioactive compounds related to hematopathy supplied as pre-dissolved Solutions or Solid.

Solution: 4,173 compounds supplied in 10 mM solution, 121 compounds supplied in 2 mM solution, 9 compounds supplied in 3 mg/mL solution.

Layout

96-well storage tube or 96-well plate: 1st and 12th column are left empty.
384-well plate: the first two columns and the last two columns are left empty.
Compounds with different concentrations or dissolved in different solvents will be put on separate plates.
This way of layout may increase the number of plates because there could be three solvents and three concentrations.
If you have other requirements, please let us know.

Container

96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode

Storage

-80°C

Shipping

Blue ice or dry ice